Stay updated on Subcutaneous Lirentelimab in Urticaria: Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the lirentelimab study is now displayed rather than an error page. It provides the study’s details, including that it is terminated and no longer recruiting, along with eligibility, locations, design, outcomes, and study documents.
    Difference
    78%
    Check dated 2026-11-08T06:10:44.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T04:11:30.000Z thumbnail image
  4. Check
    22 days ago
    Change Detected
    Summary
    A banner announces an NIH transition update, including that federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” under Executive Order 14434.
    Difference
    1%
    Check dated 2026-10-25T05:28:52.000Z thumbnail image
  5. Check
    29 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T04:45:07.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T08:17:56.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    The page now includes the study documents (SAP, Study Protocol) and IPD sharing plan, along with related metadata updates, which contextualize the trial's methodology and governance.
    Difference
    80%
    Check dated 2026-09-27T07:54:16.000Z thumbnail image

Stay in the know with updates to Subcutaneous Lirentelimab in Urticaria: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous Lirentelimab in Urticaria: Clinical Trial page.